Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

AstraZeneca (LSE:AZN) Turns to Voydeya as Danicopan Targets a Rare Blood-Disorder Opportunity

The answer is precise and deliberately narrow. Voydeya is approved in the US, the EU and Great Britain only as an add-on therapy to the C5 inhibitors ravulizumab or eculizumab in adults with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia — described …

Divya Sood | 14 July 2026

AstraZeneca (LSE:AZN) Strengthens Its Rare-Disease Portfolio With Danicopan-Based Voydeya

The strategic logic is complementarity. Voydeya is designed to address residual, clinically significant extravascular haemolysis (EVH) in patients already on a C5 backbone — a defined subgroup rather than the whole PNH population. It therefore deepens AstraZeneca's complement franchise around Ultomiris and Soliris instead …

Divya Sood | 14 July 2026

AstraZeneca (LSE:AZN) Expands Its Immunotherapy Ambitions With Durvalumab-Based Imfinzi

Rather than relying on a single blockbuster indication, AstraZeneca has widened Imfinzi across lung, gastrointestinal, genitourinary and gynaecological cancers, with approvals in the UK, EU and US. Each new indication, and each move from advanced disease into neoadjuvant or adjuvant treatment, is intended to …

Divya Sood | 14 July 2026

AstraZeneca (LSE:AZN) Bets on Imfinzi as Durvalumab Pushes Deeper Into Cancer Treatment

1.Imfinzi (durvalumab) is AstraZeneca's wholly owned anti-PD-L1 immune checkpoint inhibitor, approved across the UK, EU and US in a broadening set of cancers.

Divya Sood | 14 July 2026

Why Investors Are Closely Watching LSE:AZN Amid Oncology, AI Drug Discovery and Global Healthcare Growth

LSE:AZN - AstraZeneca PLC edged lower by approximately1.28%during today's trading session as investors booked profits following recent resilience in defensive healthcare stocks.

Ankur Sharma | 13 July 2026

Why Is LSE:HLMA - Halma plc Share Price Falling Today? Latest FTSE 100 Healthcare Technology News

LSE:HLMA - Halma plc came under modest selling pressure today, declining approximately1.98%as investors rotated away from premium valuation defensive growth stocks.

Ankur Sharma | 13 July 2026

Can RUA Life Sciences Plc Scale Its Business Globally?

RUA Life Sciences Plc (LSE: RUA)RUA Life Sciences plc develops and manufactures biostable polymer materials and components used in the design of next-generation implantable medical devices, including heart valves and vascular grafts.

Ishan Mudgal | 13 July 2026

Can Avacta Group PLC Sustain Its Position in Biotechnology & Healthcare?

Avacta Group PLC (AVCT)Avacta Group PLC is a life sciences company developing Affimer-based therapeutics and diagnostic technologies, including applications in oncology.

Ishan Mudgal | 13 July 2026

Can IXICO Plc Sustain Its Position in Biotechnology & Healthcare?

IXICO Plc (IXI)IXICO Plc provides imaging-based biomarker and data analytics services that support clinical trials for neurodegenerative diseases such as Alzheimer's and Huntington's disease.

Ishan Mudgal | 13 July 2026

Can ImmuPharma plc Sustain Its Position in Biotechnology & Healthcare?

ImmuPharma plc: Key Reasons Driving Growth, Growth Catalysts, Risks, Valuation and Technical Outlook

Ishan Mudgal | 13 July 2026
Support

Hi! How can we help you today?

Loading…